Jonathan Gootenberg (L) and Omar Abudayyeh (Suzanne Kreiter/The Boston Globe via Getty Images)

April 11, 2025 07:00 AM EDTUpdated 08:30 AM

Tome Bio founders wrangle ‘jumping genes’ to create new programmable gene insertion tool

Ryan Cross

Senior Science Correspondent

Two Boston scientists say they have developed a new gene editing tool based on mysterious “jumping genes” known as retrotransposons, which can copy and paste …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tome Bio founders wrangle ‘jumping genes’ to create new programmable gene insertion tool

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive

Makary wants to replace animal testing with organoids. It may take a while

Recruiters say some biopharmas pause hiring as they struggle to make sense of ongoing uncertainty

Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots

Pharma tariffs: Here’s what a potential rollout could look like

Bristol Myers' immunotherapy combo nets approvals in colorectal and liver cancer

Tome Bio founders wran­gle ‘jump­ing genes’ to cre­ate new pro­gram­ma­ble gene in­ser­tion tool

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Makary wants to re­place an­i­mal test­ing with organoids. It may take a while

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

Ex­clu­sive: Meri­da Bio­sciences gets $121M to treat au­toim­mune and al­ler­gy dis­eases at their roots

Phar­ma tar­iffs: Here’s what a po­ten­tial roll­out could look like

Bris­tol My­er­s' im­munother­a­py com­bo nets ap­provals in col­orec­tal and liv­er can­cer

Tome Bio founders wrangle ‘jumping genes’ to create new programmable gene insertion tool

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive

Makary wants to replace animal testing with organoids. It may take a while

Recruiters say some biopharmas pause hiring as they struggle to make sense of ongoing uncertainty

Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots

Pharma tariffs: Here’s what a potential rollout could look like

Bristol Myers' immunotherapy combo nets approvals in colorectal and liver cancer